Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study
Richard W Simpson, Geoffrey C Nicholson, Joseph Proietto, Alana Sarah, Kerrie M Sanders, Gabrielle Phillips, Jo Chambers, Rob MacGinley, Neil Orford, Ken Walder, Guy Krippner, Kathy Skoff, Vincent J Wacher
Diabetes Care | AMER DIABETES ASSOC | Published : 2014
This study was funded by Verva Pharmaceuticals, Ltd. R. W. S. received funding from Verva Pharmaceuticals, Ltd., to conduct the study and was compensated for attending advisory meetings. K. S. and V.J.W. were employed by Verva Pharmaceuticals during the course of the study, and G. K. received funding from Verva Pharmaceuticals as a consultant during the course of the study. K.W.'s laboratory at Deakin University has previously been funded by Verva Pharmaceuticals to undertake preclinical studies. No other potential conflicts of interest relevant to this article were reported.